secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001493152-26-014653
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections
---------------------------------------------------------------------------

- Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.
- Full-year 2025 CyPath Lung revenue rose 87% YoY, units sold up 99% vs 2024.
- Addressable U.S. market estimated at $3.58 billion; capturing 10% would represent $358M in sales.
- Company advancing large-scale clinical study and R&D pipeline for asthma/COPD diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226014653/0001493152-26-014653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226014653/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer